Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients.

Autor: Costedoat I; CHU de Bordeaux, National Reference Center for Rare Skin Diseases, CNRS UMR5164, ImmunoConCept, Univ. Bordeaux, Bordeaux, France., Wallaert M; Department of Dermatology and Ophthalmology, CHU Nantes, UMR 1280 PhAN, INRA, Nantes Université, Nantes, France., Gaultier A; CHU Nantes, Direction de la recherche, Plateforme de Méthodologie et Biostatistique, Nantes Université, Nantes, France., Vasseur R; Department of Dermatology and Ophthalmology, CHU Nantes, UMR 1280 PhAN, INRA, Nantes Université, Nantes, France., Vanhaecke C; Department of Dermatology-Venerology, CHU Robert-Debré, Reims, France., Viguier M; Department of Dermatology-Venerology, CHU Robert-Debré, Reims, France., Cordelette C; Department of Ophthalmology, CHU Robert-Debré, Reims, France., Denoyer A; Department of Ophthalmology, CHU Robert-Debré, Reims, France., Ferrier le Bouëdec MC; Department of Dermatology-Venerology and Ophthalmology, Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France., Coutu A; Department of Dermatology-Venerology and Ophthalmology, Centre Hospitalier Universitaire Clermont-Ferrand, Clermont-Ferrand, France., Lamiaux M; Department of Dermatology-Venerology and Ophthalmology, Lille Catholic Hospital, Lille Catholic University., Tran THC; Department of Dermatology-Venerology and Ophthalmology, Lille Catholic Hospital, Lille Catholic University., Lacour JP; Department of Dermatology-Venerology and Ophthalmology, University Hospital of Nice-Côte d'Azur, Nice, France., Elmaleh V; Department of Dermatology-Venerology and Ophthalmology, University Hospital of Nice-Côte d'Azur, Nice, France., Tetart F; Department of Dermatology-Venerology and Ophthalmology, Rouen University Hospital, Rouen, France., Gueudry J; Department of Dermatology-Venerology and Ophthalmology, Rouen University Hospital, Rouen, France., Tauber M; Department of Dermatology-Venerology and Ophthalmology, Toulouse, France., Giordano-Labadie F; Department of Dermatology-Venerology and Ophthalmology, Toulouse, France., Cassagne M; Department of Ophthalmology, Toulouse University Hospital, Toulouse, France., Nosbaum A; Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Service d'Ophtalmologie, Civils de Lyon, Pierre Bénite, France.; CIRI - Centre International de Recherche en Infectiologie (International Center for Infectiology Research), INSERM U1111, CNRS UMR, Univ Lyon, Lyon, France., Ouilhon C; Centre Hospitalier Lyon Sud, Service d'Allergologie et Immunologie Clinique, Service d'Ophtalmologie, Civils de Lyon, Pierre Bénite, France.; CIRI - Centre International de Recherche en Infectiologie (International Center for Infectiology Research), INSERM U1111, CNRS UMR, Univ Lyon, Lyon, France., Jachiet M; Faculty of Medicine, Assistance Publique-Hôpitaux de Paris (APHP), Department of Dermatology, Saint-Louis Hospital, University of Paris, Paris, France., Tadayoni R; Faculty of Medicine, Assistance Publique-Hôpitaux de Paris (APHP), Department of Ophthalmology, Lariboisiere Hospital, University of Paris, Paris, France., Dezoteux F; Centre de Référence des Syndromes Hyperéosinophiliques, Department of Dermatology-Venerology, CHU Lille, U1286 Inserm INFINITE, Université de Lille, Lille, France., Staumont-Salle D; Centre de Référence des Syndromes Hyperéosinophiliques, Department of Dermatology-Venerology, CHU Lille, U1286 Inserm INFINITE, Université de Lille, Lille, France., Bouleau J; Department of Ophthalmology, CHU Lille, Univ. Lille, Lille, France., Labalette P; Department of Ophthalmology, CHU Lille, Univ. Lille, Lille, France., Doan S; Departement of Dermatology-Venerology and Allergology, Hôpital Tenon, Paris HUEP, APHP, Paris, France.; Sorbonne Université, Paris, France.; Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France., Soria A; Departement of Dermatology-Venerology and Allergology, Hôpital Tenon, Paris HUEP, APHP, Paris, France.; Sorbonne Université, Paris, France.; Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France., Mortemousque B; CHU de Bordeaux, National Reference Center for Rare Skin Diseases, CNRS UMR5164, ImmunoConCept, Univ. Bordeaux, Bordeaux, France., Seneschal J; CHU de Bordeaux, National Reference Center for Rare Skin Diseases, CNRS UMR5164, ImmunoConCept, Univ. Bordeaux, Bordeaux, France., Barbarot S; Department of Dermatology and Ophthalmology, CHU Nantes, UMR 1280 PhAN, INRA, Nantes Université, Nantes, France.
Jazyk: angličtina
Zdroj: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2023 May; Vol. 37 (5), pp. 1056-1063. Date of Electronic Publication: 2023 Feb 16.
DOI: 10.1111/jdv.18932
Abstrakt: Background: Although ocular adverse events are frequent in AD patients treated with dupilumab, their characterization remains limited due to a lack of prospective studies with a systematic ophthalmological examination.
Objective: To examine the incidence, characteristics and risk factors of dupilumab-induced ocular adverse events.
Methods: A prospective, multicenter, and real-life study in adult AD patients treated with dupilumab.
Results: At baseline, 27 out of 181 patients (14.9%) had conjunctivitis. At week 16 (W16), 25 out of 27 had improved their conjunctivitis and 2 remained stable and 34 out of 181 patients (18.7%) had dupilumab-induced blepharoconjunctivitis: either de novo (n = 32) or worsening of underlying blepharoconjunctivitis (n = 2). Most events (27/34; 79.4%) were moderate. A multivariate analysis showed that head and neck AD (OR = 7.254; 95%CI [1.938-30.07]; p = 0.004), erythroderma (OR = 5.635; 95%CI [1.635-21.50]; p = 0.007) and the presence of dry eye syndrome at baseline (OR = 3.51; 95%CI [3.158-13.90]; p = 0.031) were independent factors associated with dupilumab-induced blepharoconjunctivitis.
Limitations: Our follow-up period was 16 weeks and some late-onset time effects may still occur.
Conclusion: This study showed that most dupilumab-induced blepharoconjunctivitis cases are de novo. AD severity and conjunctivitis at baseline were not found to be associated risk factors in this study.
(© 2023 European Academy of Dermatology and Venereology.)
Databáze: MEDLINE
Externí odkaz: